NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Converge Bio

Converge Bio

Private
Tel AvivHealthcare & Life Scienceshttps://converge-bio.com/

Last Round

Grant

Jun 2, 2026

Est. Valuation

$90M

Total Funding Raised

$33M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Converge Bio is a biotechnology company that provides a generative AI platform using large language models trained on biological and chemical data to accelerate drug discovery and development for pharmaceutical companies.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, NLP & Conversational AI, ML Platforms

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

drug discoverygenerative AIantibody designprotein engineeringbio-LLMin silico drug discoverybiotech AItarget discoveryprotein yield optimizationbiomarker discoveryAI drug developmentlarge language modelsLLMcomputational biologySaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Converge Bio Comps

Public and private peers based on sector, stage, and business model.

Converge Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Converge Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 2, 2026
Early Stage VCApr 28, 2026
Series AJan 13, 2026
SeedNov 20, 2024

Key People

Founding team and executive leadership

Oded Kalev

CTO Co Founder

Founding Team

Dov Gertz

CEO Co-Founder

Founding Team

Converge Bio Investors

Notable investors and investment history

Converge Bio investors
InvestorRounds
Saras CapitalSeries A
Vintage Investment PartnersSeries A
TLV PartnersSeries A, Seed
Bill & Melinda Gates FoundationGrant
Bessemer Venture PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 28, 2026

    $25M raised in early stage VC round.

  • Jan 13, 2026

    $25M round completed.

Converge Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Converge Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Converge Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range52
Year Founded2024
Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.